Difference between revisions of "Team:BGU Israel"
| Line 27: | Line 27: | ||
margin-bottom: 30px !important; | margin-bottom: 30px !important; | ||
} | } | ||
| + | .bg-gray { | ||
| + | background-color:#ededed; | ||
| + | color:#000; | ||
| + | } | ||
| + | .bg-white { | ||
| + | background-color:#fff; | ||
| + | color:#000; | ||
| + | } | ||
| + | .bg-dark { | ||
| + | background-color:#262626; | ||
| + | color:#fff; | ||
| + | } | ||
h4 { | h4 { | ||
font-size: 19px; | font-size: 19px; | ||
| Line 204: | Line 216: | ||
padding-bottom: calc(10rem - 56px); | padding-bottom: calc(10rem - 56px); | ||
background-image:url('https://static.igem.org/mediawiki/2018/2/2e/T--BGU_Israel--home_banner.jpg'); | background-image:url('https://static.igem.org/mediawiki/2018/2/2e/T--BGU_Israel--home_banner.jpg'); | ||
| − | + | width:100%; | |
overflow: hidden; | overflow: hidden; | ||
min-height: 700px; | min-height: 700px; | ||
| Line 244: | Line 256: | ||
background-color: #555; | background-color: #555; | ||
} | } | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
.navbar-default .navbar-nav>.open>a, .navbar-default .navbar-nav>.open>a:focus, .navbar-default .navbar-nav>.open>a:hover { | .navbar-default .navbar-nav>.open>a, .navbar-default .navbar-nav>.open>a:focus, .navbar-default .navbar-nav>.open>a:hover { | ||
| Line 407: | Line 407: | ||
border:0; | border:0; | ||
} | } | ||
| + | .container-fluid { | ||
| + | padding: 60px 50px; | ||
| + | } | ||
| + | |||
| + | .bg-grey { | ||
| + | background-color:#ededed; | ||
| + | color:#000; | ||
| + | padding: 60px 50px; | ||
| + | } | ||
| + | .bg-white { | ||
| + | background-color:#fff; | ||
| + | color:#000; | ||
| + | padding: 60px 50px; | ||
| + | } | ||
| + | .bg-dark { | ||
| + | background-color:#262626; | ||
| + | |||
| + | padding: 60px 50px; | ||
| + | } | ||
| + | .bg-dark h1 { | ||
| + | color:#fff !important; | ||
| + | |||
| + | } | ||
| + | footer.bg-dark p { | ||
| + | color:#ededed !important; | ||
| + | } | ||
| + | .social-icons { | ||
| + | display: inline; | ||
| + | height:20px; | ||
| + | width:20px; | ||
| + | margin-right:10px; | ||
| + | } | ||
| + | |||
</style> | </style> | ||
| − | <footer> | + | <footer class="bg-dark"> |
<div class="container my-auto"> | <div class="container my-auto"> | ||
<div class="row"> | <div class="row"> | ||
<div class="col-md-4"> | <div class="col-md-4"> | ||
| − | < | + | <h3>About OrignALS</h3> |
| − | + | <p><br>Established in 2006, EchoSense Ltd. develops innovative ultrasound Doppler systems for the diagnosis and monitoring of cardiac and pulmonary diseases. EchoSense delivers a fast,reliable and non-invasive method of diagnosis and our technology has undergone successful clinical trials in the United States, Europe and Israel. The Echosense research and development center is based in Haifa, Israel.</p> | |
| − | + | <img class="responsive-img" src="originals_white.png" width="50%"> | |
| − | + | ||
| − | + | <img class="img-responsive" src=""> | |
| − | + | ||
</div> | </div> | ||
<div class="col-md-4"> | <div class="col-md-4"> | ||
<ul class="footer-list"> | <ul class="footer-list"> | ||
| − | <li class="footer-list-item"> | + | <h3>Keep in Touch</h3> |
| − | <li class="footer-list-item"> | + | |
| − | <li class="footer-list-item"> | + | <li class="footer-list-item"><img class="img-responsive social-icons" src="facebook.png" > @iGEMBGU</li> |
| + | <li class="footer-list-item"><img class="img-responsive social-icons" src="instagram.png" >@igem_2018_bgu</li> | ||
| + | <li class="footer-list-item"><img class="img-responsive social-icons" src="twitter.png" > @originalsbgu</li> | ||
| + | <li class="footer-list-item"><img class="img-responsive social-icons" src="email.png" > bgu_israel@gmail.com</li> | ||
</ul> | </ul> | ||
</div> | </div> | ||
<div class="col-md-4"> | <div class="col-md-4"> | ||
<ul class="footer-list"> | <ul class="footer-list"> | ||
| − | + | <h3>Address</h3> | |
| − | <li class="footer-list-item"> | + | <li class="footer-list-item">Ben-Gurion University of the Negev<br> |
| − | <li class="footer-list-item"> | + | Ben Gurion 1, Beer Sheva 8410501, Israel</li> |
| − | + | ||
| + | <li class="footer-list-item"><img class="responsive-img" src="bgu_white.png"></li> | ||
</ul> | </ul> | ||
</div> | </div> | ||
Revision as of 11:10, 22 August 2018
<!DOCTYPE html>
Abstract
Recent research studies of Amyotrophic Lateral Sclerosis (ALS) suggest that brain cells that have become toxic, directly contribute to the progression of the disease. These cells change their gene expression pattern and possess distinguishing genetic markers. In addition, they drive the death of other cells in the brain among them the motor neurons.
Our objective, as the BGU-IGEM team OriginALS, is to prolong survival of ALS patients via a novel genetic engineering approach. In order to reach this objective, we combine two separate strategies as our therapeutic approach:
- We identify and selectively eliminate only the toxic cells. In order to identify and target the toxic-cells only, we use distinguishing markers that are unique only to them.
- We prevent the generation of new toxic cells by genetically targeting specific molecules that generate the toxic cells.
In conclusion, our approach combines an apoptotic destruction of toxic cells with the prevention of the formation of new toxic cells, thus aiming to significantly reduce the occurrence of toxic cells in the central neuronal system (CNS), which is aimed at a significant deceleration of the progression rate of ALS.